Myelofibrosis
Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
Melissa BadamoMyelofibrosis | November 17, 2023
Researchers also observed potential disease modification via rapid stabilization of platelets and stable hemoglobin levels.
Read More
Patrick DalyMyelofibrosis | November 16, 2023
There were no significant differences in response rates with pegylated interferon-alpha versus hydroxyurea in MPN treatment.
Melissa BadamoMyelofibrosis | November 16, 2023
The trial is based on “compelling data” from arm III of the ongoing phase II MANIFEST study.
Melissa BadamoMyelofibrosis | October 13, 2023
82.5% of MF patients experienced rapid significant decreases in palpable spleen size after two months of ruxolitinib therapy.
Melissa BadamoMyelofibrosis | October 13, 2023
The median duration of therapy is around three years in patients with intermediate or high-risk MF.
Patrick DalyMyelofibrosis | October 12, 2023
The analysis included 346 patients with CALR-mutated MF who were transplanted in 123 centers between 2005 and 2019.
Advertisement
Sangeetha Venugopal, MDMyelofibrosis | September 20, 2023
Myelofibrosis Awareness Day is marked on September 20th each year.
Leah LawrenceMeeting News | September 19, 2023
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Leah LawrenceMyelofibrosis | September 19, 2023
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Leah LawrenceMyelofibrosis | September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Leah SherwoodMyelofibrosis | September 16, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Cecilia BrownMyelofibrosis | August 21, 2023
Ruxolitinib, an oral JAK1/JAK2 inhibitor, initially received FDA approval in 2011.
Cecilia BrownMyelofibrosis | August 21, 2023
Researchers conducted the study because the mechanism by which pacritinib improves anemia has not been elucidated.
Cecilia BrownMyelofibrosis | August 18, 2023
Researchers conducted an indirect comparison analysis of multiple clinical trials to address the question.
Leah SherwoodMyelofibrosis | August 9, 2023
In June 2023, the manufacturer of the drug initiated XPORT-MF-034, a pivotal phase III clinical trial.
Leah SherwoodIndolent B-Cell Lymphoma | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Cecilia BrownMyelofibrosis | July 14, 2023
At a median follow-up of 55 weeks, 90% of patients completed 24 weeks of treatment and 56% completed 48 weeks of treatment.
Cecilia BrownMyelofibrosis | July 13, 2023
Initiation of ruxolitinib therapy within two years of diagnosis was associated with increased response rates in all patients.
Cecilia BrownMyeloproliferative Neoplasms | June 20, 2023
Just under half (43%) of patients receiving ruxolitinib achieved a CR, while 26% achieved a CR on the best available therapy.
Cecilia BrownMyeloproliferative Neoplasms | June 16, 2023
However, achieving a spleen volume reduction on the best available therapy was not linked with improved survival.
Advertisement
Advertisement
Editorial Board